Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance

Cancer Research

Volumn 62, Issue 17, 2002, Pages 5035-5040

  Volk, Erin L ^a,b   Farley, Kate M ^a,b   Wu, Yan ^a,b   Li, Fei ^a,b   Robey, Robert W ^c   Schneider, Erasmus ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME SPECIFICITY; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIMETABOLITES, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; METHOTREXATE; NEOPLASM PROTEINS; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0036732010     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Selective multiplication of dihydrofolate reductase genes in methotrexate resistant variants of cultured murine cells
2. Identification and characterization of a mutation in the dihydrofolate reductase gene from the methotrexate-resistant Chinese hamster ovary cell line Pro-3 MtxRIII
3. Allelic variation in the dihydrofolate reductase gene at amino acid position 95 contributes to antifolate resistance in Chinese hamster cells
4. Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug
5. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells
6. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance
7. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues
8. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis
9. Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell
10. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity
11. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux
12. Transport energetics of the folic acid analogue, methotrexate, in L1210 leukemia cells. Enhanced accumulation by metabolic inhibitors
13. Effects of metabolic deprivation on methotrexate transport in L1210 leukemia cells: Further evidence for separate influx and efflux systems with different energetic requirements
14. The issues of transport multiplicity and energetics pertaining to methotrexate efflux in L1210 cells addressed by an analysis of cis-and trans-effects of inhibitors
15. Energy-dependent efflux of methotrexate in L1210 leukemia cells
16. Retentiveness of methotrexate polyglutamates in cultured L1210 cells
17. Structural preferences among folate compounds and their analogues for ATPase-mediated efflux by inside-out plasma membrane vesicles derived from L1210 cells
18. Identification of efflux systems for large anionic conjugates as the mediators of methotrexate efflux in L1210 cells
19. Methotrexate and γ-tert-butyl methotrexate transport in CEM and CEM/MTX human leukemic lymphoblasts
20. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)
21. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
22. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells
23. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
24. The product of the ABC half transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane
25. A multidrug resistance transporter from human MCF-7 breast cancer cells
26. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
27. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes
28. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
29. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
30. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
31. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells
32. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance
33. A human cell line from a pleural effusion derived from a breast carcinoma
34. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant MCF-7 breast cancer cells
35. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line
36. Overexpression of the ATP-binding cassette half-transporter. ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells
37. Decreased melphalan accumulation in a breast cancer cell line selected for resistance to melphalan
38. Fojo. A. Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein
39. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)
40. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257
41. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C
42. Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone
43. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance
44. New colorimetric cytotoxicity assay for anticancer-drug screening
45. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
46. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
47. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins using non-substrate drugs or the BCRP inhibitor GF120918
48. Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan
49. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
50. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines
51. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport